🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 80 of 857 · Phase 3 first, then by program name

  1. Humira 20 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg/0.8 ml solution for injection

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  2. Humira 40 mg solution for injection in pre-filled syringe, Abatacept

    Bristol-Myers Squibb Australia Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  3. Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution

    The George Institute

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  4. Humira 40 mg solution for injection in pre-filled syringe, Risankizumab, Humira 20 mg solution for injection in pre-filled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881

    Takeda

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  6. Hyalobarrier

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Thyroid Disease

    phase 3 other completed

    1 trial

  7. Hydrocodone ER

    Teva Pharma GmbH

    Chronic Pain

    phase 3 small molecule completed

    2 trials

  8. Hydrocodone ER

    Teva Pharma GmbH

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  9. Hydrocortisone

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    2 trials

  10. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Pain

    phase 3 small molecule completed

    1 trial

  11. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  12. Hypnotic Medication Open-Label Taper

    BRIGHT MINDS BIOSCIENCES INC.

    Hypnotic Dependence Among Those With Insomnia

    phase 3 other active

    1 trial

  13. I004

    Amphastar France Pharmaceuticals

    Pharmacokinetics

    phase 3 small molecule active

    2 trials

  14. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  15. IAE0972+ Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NPC

    phase 3 mab active

    1 trial

  16. IBI363

    Takeda

    iO Resistant sqNSCLC

    phase 3 small molecule active

    1 trial

  17. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  18. IBRANCE 125 mg film-coated tablets, Placebo Giredestrant, IBRANCE 100 mg hard capsules, RO7197597, Placebo Letrozole, IBRANCE 75 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, Femara® 2,5 mg Filmtabletten, IBRANCE 100 mg film-coated tablets

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  19. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  20. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  21. IC51

    Valneva Austria GmbH

    Encephalitis

    phase 3 mab completed

    1 trial

  22. ICM ADX-2191 injection

    Aldeyra Therapeutics

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  23. ICT-107

    Chongqing Precision Biotech Co., Ltd

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials

  24. IDE196

    IDEAYA Biosciences

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources